{"url_path":"/sec/icu/8-k/2026-06-17/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1831868/0001437749-26-020967-index.html","accession_number":"0001437749-26-020967","cik":"0001831868","ticker":"ICU","issuer_name":"SeaStar Medical Holding Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1831868/0001437749-26-020967-index.html","primary_entity_key":"0001831868","primary_entity_name":"SeaStar Medical Holding Corp"},"word_count":174,"has_tables":true,"body_markdown":"**Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nAs described in Item 5.07 below, on June 17, 2026, the annual meeting of stockholders (the “Annual Meeting”) of SeaStar Medical Holding Corporation (the “Company”) was held in order to, among other items, approve an amendment and restatement of the Company’s 2022 Omnibus Incentive Plan (the “2022 Equity Incentive Plan”) to increase the number of authorized shares of common stock, $0.0001 par value (the “Common Stock”) from 207,046 shares to 896,546 shares.\n\n \n\nA summary of the 2022 Equity Incentive Plan is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). That summary and the above description of the 2022 Equity Incentive Plan do not purport to be complete and are qualified in their entirety by reference to the 2022 Equity Incentive Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference."}